St. Jude Medical landed FDA approval of its MultiPoint pacing technology that is available through the Quadra Assura MP cardiac resynchronization therapy defibrillator, the Quadra Allure MP CRT-pacemaker, and two of the company’s quadripolar Quartet LV leads.
The technology allows a greater range of pacing options that may help improve how patients respond to the signals delivered by the implants. When St. Jude Medical introduced quadripolar leads in 2011, physicians were able to program a single pacing pulse from one of four electrodes on the lead. The MultiPoint pacing technology can be programmed to deliver pacing pulses from two of those four electrodes (on the single lead), increasing the pacing options for patients.
More from St. Jude:
St. Jude Medical also announced FDA approval of additional quadripolar pacing Quartet LV leads, which can be used with MultiPoint Pacing technology, as well as the programmer-based Auto VectSelect Quartet™ Test. The two new leads are designed based on the company’s first-to-market, clinically proven Quadripolar LV lead technology and include additional electrode spacing options on two new S-curve shaped lead designs. The expanded family of Quartet LV leads offers more options to effectively meet the needs of patients with larger as well as smaller cardiac anatomies. Physicians can quickly customize therapy using the new automated Auto VectSelect Quartet Test, which is designed to offer comprehensive testing results so appropriate therapy options can be easily and efficiently programmed for each patient in a streamlined workflow.
Source: St. Jude Medical…